A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

NCT04501094 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

NIH

Sponsor class

Stopped Because of the low accrual and the safety concerns we closed the study.

Conditions

Urothelial Cancer

Interventions

DRUG: Bintrafusp alfa (M7824)

Sponsor

National Cancer Institute (NCI)